PMCH and inflammatory bowel disease: In parallel, it will allow for the identification of previously unappreciated pathways of importance to the pathogenesis of IBD and effective screening of new drug candidates, including agents targeting MCH, or repurposing of old drugs as has been recently suggested for a mu-opioid agonist based on its effects on a zebrafish model of intestinal injury [28].